Literature DB >> 1538149

Immunity in hepatitis C infection.

A M Prince1, B Brotman, T Huima, D Pascual, M Jaffery, G Inchauspé.   

Abstract

Polymerase chain reaction (PCR) and newer serologic assays for hepatitis C virus (HCV) were used to investigate 19 HCV cross-challenge episodes in chimpanzees. In these cross-challenges, 59% showed seroconversion after challenge, 33% showed reappearance of HCV-associated hepatocellular ultrastructural changes, 5 animals not PCR-positive at the time of challenge showed return of PCR positivity, and 26% developed hepatitis after rechallenge. A total of 74% showed at least one of these signs of reinfection. The frequency of development of serologic and ultrastructural responses was, however, reduced in secondary compared with primary infections (P less than .01). In 10 animals, the cross-challenge was done with heterologous strains, and in 9 with the originally infecting virus. There was no significant difference in the responses to homologous and heterologous challenges. The data suggest relatively weak immunity in HCV infections.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1538149     DOI: 10.1093/infdis/165.3.438

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  53 in total

1.  Interferon-alpha for reinfection with hepatitis C virus in two patients with chronic hepatitis C who had responded to previous therapies.

Authors:  Norio Akuta; Fumitaka Suzuki; Akihito Tsubota; Yoshiyuki Suzuki; Takashi Someya; Masahiro Kobayashi; Satoshi Saitoh; Yasuji Arase; Kenji Ikeda; Yuzo Miyakawa; Hiromitsu Kumada
Journal:  Dig Dis Sci       Date:  2003-08       Impact factor: 3.199

2.  Exposure to low infective doses of HCV induces cellular immune responses without consistently detectable viremia or seroconversion in chimpanzees.

Authors:  Mohamed Tarek Shata; Nancy Tricoche; Marion Perkus; Darley Tom; Betsy Brotman; Patricia McCormack; Wolfram Pfahler; Dong-Hun Lee; Leslie H Tobler; Michael Busch; Alfred M Prince
Journal:  Virology       Date:  2003-09-30       Impact factor: 3.616

3.  Molecular epidemiology of hepatitis C among drug users in Flanders, Belgium: association of genotype with clinical parameters and with sex- and drug-related risk behaviours.

Authors:  C Matheï; E Wollants; J Verbeeck; M Van Ranst; G Robaeys; P Van Damme; F Buntinx
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2005-08       Impact factor: 3.267

4.  Intrahepatic genetic inoculation of hepatitis C virus RNA confers cross-protective immunity.

Authors:  A J Weiner; X Paliard; M J Selby; A Medina-Selby; D Coit; S Nguyen; J Kansopon; C L Arian; P Ng; J Tucker; C T Lee; N K Polakos; J Han; S Wong; H H Lu; S Rosenberg; K M Brasky; D Chien; G Kuo; M Houghton
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

5.  Functional role of hepatitis C virus chimeric glycoproteins in the infectivity of pseudotyped virus.

Authors:  L M Lagging; K Meyer; R J Owens; R Ray
Journal:  J Virol       Date:  1998-05       Impact factor: 5.103

Review 6.  Gene vaccination for hepatitis C.

Authors:  G Inchauspé
Journal:  Springer Semin Immunopathol       Date:  1997

7.  Prevalence and significance of hepatitis C virus (HCV) viremia in HCV antibody-positive subjects from various populations.

Authors:  M François; F Dubois; D Brand; Y Bacq; C Guerois; C Mouchet; J Tichet; A Goudeau; F Barin
Journal:  J Clin Microbiol       Date:  1993-05       Impact factor: 5.948

8.  Mapping of serotype-specific, immunodominant epitopes in the NS-4 region of hepatitis C virus (HCV): use of type-specific peptides to serologically differentiate infections with HCV types 1, 2, and 3.

Authors:  P Simmonds; K A Rose; S Graham; S W Chan; F McOmish; B C Dow; E A Follett; P L Yap; H Marsden
Journal:  J Clin Microbiol       Date:  1993-06       Impact factor: 5.948

Review 9.  Neutralizing antibodies in hepatitis C virus infection.

Authors:  Mirjam-B Zeisel; Samira Fafi-Kremer; Isabel Fofana; Heidi Barth; Francoise Stoll-Keller; Michel Doffoel; Thomas-F Baumert
Journal:  World J Gastroenterol       Date:  2007-09-28       Impact factor: 5.742

10.  Peptide immunogen mimicry of putative E1 glycoprotein-specific epitopes in hepatitis C virus.

Authors:  R Ray; A Khanna; L M Lagging; K Meyer; Q L Choo; R Ralston; M Houghton; P R Becherer
Journal:  J Virol       Date:  1994-07       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.